Angiopoietin‐like protein 2 and mortality in patients with heart failure—Results from an observational study
European Journal of Clinical Investigation · 2026
DOI: 10.1111/eci.70143 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Eva Maria Brandtner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 2, Heart Failure. Die Arbeit nennt 29 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure is an advanced form of cardiovascular disease with a high mortality rate. Management of the condition is possible and blood‐based biomarkers could help identify the most vulnerable patients. There is mounting evidence of a link between angiopoietin‐like protein 2 (ANGPTL2), a secreted glycoprotein involved in inflammation and tissue remodelling, and heart failure. However, no prospective studies have examined whether ANGPTL2 predicts mortality in heart failure, which this study aims to address.
Methods
Mortality was prospectively recorded in a cohort of 303 patients with heart failure over a period of 5 years. Serum ANGPTL2 levels were determined at baseline by means of enzyme‐linked immunosorbent assay.
Results
At baseline, elevated ANGPTL2 levels were highly significantly associated with increased concentrations of total, LDL‐ and HDL‐cholesterol and with a lower prevalence of male sex, smoking history, cardiovascular disease and statin use. During the five‐year follow‐up period, 47% of all patients died. When patients were stratified into tertiles based on ANGPTL2 levels, those in the highest tertile exhibited a significantly increased risk of all‐cause mortality compared to those in the lowest tertile (hazard ratio = 1.88 [1.23–2.88]; p = .004). After adjustment for potential confounders, including NT‐proBNP, the association remained significant, with an adjusted hazard ratio of 1.91 [1.13–3.23]; p = .015. In addition, the inclusion of ANGPTL2 improved the predictive accuracy of a model based on traditional risk factors, as indicated by a significant 24.3% net reclassification improvement.
Conclusion
Circulating ANGPTL2 is a significant predictor of mortality in patients with heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria.
- Medical Central Laboratories, Feldkirch, Austria.
- Private University in the Principality of Liechtenstein, Triesen, Liechtenstein.
- Department of Internal Medicine I, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.
- Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Laura Schnetzer, Axel Muendlein
Zitieren
APA
Brandtner, E. M., Leiherer, A., Larcher, B., Geiger, K., Heinzle, C., Schnetzer, L., Saely, C. H., Drexel, H., & Muendlein, A. (2026). Angiopoietin‐like protein 2 and mortality in patients with heart failure—Results from an observational study. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70143
Vancouver
Brandtner EM, Leiherer A, Larcher B, Geiger K, Heinzle C, Schnetzer L, et al. Angiopoietin‐like protein 2 and mortality in patients with heart failure—Results from an observational study. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70143
BibTeX
@article{Brandtner2026,
author = {Brandtner, Eva Maria and Leiherer, Andreas and Larcher, Barbara and Geiger, Kathrin and Heinzle, Christine and Schnetzer, Laura and Saely, Christoph H and Drexel, Heinz and Muendlein, Axel},
title = {Angiopoietin‐like protein 2 and mortality in patients with heart failure—Results from an observational study},
journal = {European Journal of Clinical Investigation},
year = {2026},
doi = {10.1111/eci.70143}
}
EUVIMED